Figure 1: A screen to discover compounds that decrease the OCR of FaDu cells.
From: The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia
(a) For the primary screen, FaDu cells were grown in galactose-containing medium and incubated with a library of 1697 FDA-approved compounds for 24 h. The mitochondrial specific OCR was measured, and subsequent hoechst staining was used to correct for cell number. (b) For the secondary screen, FaDu cells were grown in glucose-containing medium, incubated with the compounds for 24 h, and then the mitochondrial-specific OCR was measured and normalized to cell number. (c–e) The OCR of FaDu, HCT116 and H1299 cells were measured for 4.5 h after injection of atovaquone. The % OCR post injection is shown relative to the DMSO control and normalized to the relative cell number obtained by hoechst staining at the end of the experiment. The data are representative of three independent experiments (mean±s.d.). One-way ANOVA were performed to assess statistical significance at 4.5 h after injection of atovaquone with Bonferroni post correction (*P<0.0001). ATO, atovaquone.
